Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001104659-25-002505·Lakefront Biotherapeutics NV
Schedule 13D ownership disclosure
LAKEFRONT BIOTHERAPEUTICS NV
Ordinary Shares, no par value · CUSIP: 36315X101
Event date: 2025-01-07
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Gilead Sciences, Inc.Reported CIK 0000882095
Shares: 20,981,010.00 · Class: 29.9%
- Gilead Therapeutics A1 Unlimited Company
Shares: 20,981,010.00 · Class: 29.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-002505
- Form type
- SCHEDULE 13D/A
- Filer
- Lakefront Biotherapeutics NV
- CIK
- CIK 1421876
- Filed
- Jan 10, 2025
- Reporting period
- Jan 07, 2025
- Description
- Schedule 13D beneficial ownership